Royalty Report: Drugs, Cancer, Drug Discovery – Collection: 315793


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Cancer
  • Drug Discovery
  • cardiac
  • Ophthalmological
  • Pharmaceuticals
  • Delivery
  • Disease
  • DNA
  • Genome
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 315793

License Grant
Licensor grants to Licensee an exclusive license under Licensor Patent Rights and Licensor Know-how to develop, make, have made, use, sell, offer to sell and import  Licensed Products in the Territory with the right to grant sublicenses.

Licensor grants to Licensee an irrevocable Option during the Option Period to obtain an exclusive license from Licensor in the Territory, under Licensor Patent Rights and Licensor Know-how, to develop, make, have made, use, sell, offer to sell and import, Licensed Products containing Compounds which are VEGF Material.

License Property
Valid Patent Rights means issued and unexpired Licensor Patent Rights which have not been revoked or held unenforceable or invalid by a court or other governmental agency of competent jurisdiction, unappealed or unappealable within the time allowed for appeal, and which has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue or disclaimer or otherwise.

5,580,859 – Delivery of exogenous DNA sequences in a mammal
5,589,466 – Induction of a protective immune response in a mammal by injecting a DNA sequence

Licensed Product means preparations in final form for sale by prescription, over the counter or any other method for all uses, in humans which contain Compound, including, without limitation, any combination product.

Compound means FGF Material.

FGF Material means plasmid constructs of fibroblast growth factors (FGF), including FGF-1 (aFGF), coding all alleles, alternatively spliced isoforms, mutants and forms containing artificial secretory leader sequences that have among their biologic activities angiogenic and/or vascular endothelial cell mitogenic activity. FGF Material encompasses FGF-1 through FGF-12 and homologous family members including any FGF homologues that are or will be identified with at least 62% sequence homology and that have among their.biologic activities angiogenic and/or vascular endothelial cell mitogenic activity.

Option means the option to obtain rights under Licensor Patent Rights with respect to VEGF Material.

Licensor is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases including methods for the administration of plasmid DNA to humans, which DNA expresses physiologically active proteins for human therapeutic applications.

Field of Use
The rights granted apply to the use of the Technology for pharmaceutical products with mechanisms of action mediated by fibroblast growth factor (FGF) and/or vascular endothelial growth factor (VEGF).

Licensee is a premier research-intensive biopharmaceutical company researching to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases, such as HIV and Ebola, and emerging animal diseases.

IPSCIO Record ID: 233425

License Grant
Licensor grants a nonexclusive, nonsublicensable, nontransferable license under Licensors Patents, for the sole purpose of using, making, having made and selling the Final Products, where such Final Products are sold to Licensor for distribution by Licensor, all in accordance with the terms and conditions of this Agreement.
License Property
The patents are worldwide including but not limited to U.S. Patents  5,661,133 and 6,316,419.

Injection Catheter means the injection catheter known as the Stilettoâ„¢ manufactured by Licensor, including improvements, modifications and replacements thereto.

Product means a plasmid DNA, drug, biologic or other composition comprising VEGF-2.  Product does not include any delivery device, including without limitation the Injection Catheter, a hypodermic needle or stent, or the combination of any such plasmid DNA, drug, biologic or other composition with any such delivery device.

VEGF-2 means the Human Genome Sciences angiogenic agent licensed to and being further developed and modified by the Company, sometimes referred to as Vascular Endothelial Growth Factor 2 plasmid DNA, and any modifications or improvements thereto.

Field of Use
The property is used for treatment of diseases of the heart or peripheral vascular system.

IPSCIO Record ID: 311

License Grant
Licensor hereby grants to each Licensee a non-exclusive, worldwide license under the Licensed Patents for the Term of this Agreement to make, have made, use, offer for sale, sell, import, and export Licensed Product in the Field in the Territory.
License Property
“Licensed Product” shall mean the protein aflibercept, whether sold under the trade name Zaltrap or any other name, and any pharmaceutical formulation of the protein aflibercept with one or more excipients, in each case that is intended for use in the Field in the Territory.
ZALTRAP is an FDA-approved anti-cancer medicine given in combination with a chemotherapy regimen called FOLFIRI (foal-feer-ee) to treat colorectal cancer that has spread.

IP relates to the Davis-Smyth patents, and certain other patents, in all indications for human use other than the prevention or treatment of eye diseases and eye disorders through administration to the eye. Under the terms of the ZALTRAP Agreement, payments are required to be made to licensor based on sales of ZALTRAP in the United States and of ZALTRAP that is manufactured in the United States and sold outside the United States through May 7, 2016.

The partner commenced sales of ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion, in combination with 5-fluorouracil, leucovorin, irinotecan ('FOLFIRI'), for patients with metastatic colorectal cancer (“mCRC”) that is resistant to or has progressed following an oxaliplatin-containing regimen, in the United States in the third quarter of 2012 and in certain European and other countries in the first quarter of 2013.

The licensee and partner globally collaborate on the development and commercialization of ZALTRAP.

Licensed Patents
.S. Patent No. 5,952,199
U.S. Patent No. 6,100,071
U.S. Patent No. 6,383,486
U.S. Patent No. 6,897,294
U.S. Patent No. 7,771,721
U.S. Patent No. 8,268,313
U.S. Patent No. 8,268,591
U.S. Patent No. 8,273,353
U.S. Patent Application No. 08/643,839
U.S. Patent No. 7,998,931
U.S. Patent No. 8,007,799
U.S. Patent No. 8,287,873
U.S. Patent Application No. 12/002,605

Field of Use
“Field” shall mean and be limited to the prevention or treatment of any disease or condition in a human through the administration of Licensed Product, excluding only the Ocular Field. As used herein, “Ocular Field” shall mean the prevention or treatment of eye diseases and eye disorders in a human through the administration of Licensed Product to the eye (including, but not limited to, the prevention or treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and/or myopic choroidal neovascularization in a human).

IPSCIO Record ID: 203979

License Grant
Licensor grants a nonexclusive, non-transferable, worldwide license, without the right to grant sublicenses, under Licensors technology and patents to perform research and preclinical development in the field during the research term using Licensee research genes.

Licensor grants non-exclusive, non-transferable options to obtain licenses for up to three (3) Licensee identified Research Genes exercisable during the research term of this Agreement.

With respect to exclusive Licensee products directed to a Licensee research gene for which Licensee has exercised an option Licensor is obligated to grant a license.  Licensor grants to Licensee an exclusive worldwide license under Licensor technology and patents to research, develop, make, have made, use, import, export, offer to sell and sell such exclusive Licensee products in the field.

License Property
The Licensed patents include the Delivery of Exogenous DNA Sequences in a Mammal and the Production of Pharmaceutical-Grade Plasmid DNA.
Field of Use
The field is the intervention, treatment and/or prevention of a disease or disorder in humans by Gene therapy.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.